Structural characterization of Fab-dimerized glycan-reactive antibodies that neutralize HIV-1

中和 HIV-1 的 Fab 二聚聚糖反应性抗体的结构表征

基本信息

  • 批准号:
    10403172
  • 负责人:
  • 金额:
    $ 70.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-17 至 2026-08-31
  • 项目状态:
    未结题

项目摘要

Structural characterization of Fab-dimerized glycan-reactive antibodies that neutralize HIV-1 A glycan shield covers the HIV-1 envelope (Env) limiting antibody access to broadly neutralizing antibody (bnAb) epitopes. 2G12 had for long been the only example of a HIV-1 bnAb that interacts solely with the Env glycan shield. Its unique VH domain-swapped architecture, with two Fab arms swapped to create a Fab-dimerized IgG, allows 2G12 to simultaneously interact with 4 glycans, thus bolstering typically weak protein-glycan binding through avidity. We have recently characterized structurally diverse Fab-dimerized, glycan-reactive (FDG) antibodies that target the HIV-1 Env glycan shield. Unlike 2G12, these newly identified FDG antibodies are not domain-swapped; instead, Fab dimerization occurred by mechanisms including inter- Fab disulfide linkage, hydrophobic and hydrogen bond interactions. We further showed that the HIV-1 Env- targeting FDG antibodies recognized a glycan cluster in the S2 subunit of the SARS-CoV-2 spike. While our results reveal diverse ways antibodies can Fab dimerize to recognize glycans clusters, several questions remain regarding the mechanisms of Fab dimerization and glycan recognition. Understanding these will provide insights into the development of B cell responses to glycans. The overall goals of this study are to understand structural determinants of antibody Fab dimerization leading to high affinity glycan recognition. That 2G12 and other FDG bnAbs specifically recognize a conserved glycan cluster on HIV-1 Envs that consists of self-sugars in a unique non-self presentation provides basis for immunological discrimination between glycans on host and invading pathogens. The scientific premise of this grant is that defining structural mechanisms for glycan recognition by Fab dimerized antibodies will allow specific targeting of diverse glycosylated pathogens. The innovations in this grant derive from (i) an expanded repertoire of FDG antibodies, (ii) the demonstration that FDG antibodies are prevalent, (iii) the finding that domain-swapped VH conformation is not necessary for HIV-1 neutralization.
中和HIV-1的Fab-二聚聚糖反应性抗体的结构表征 聚糖盾覆盖HIV-1包膜(Env),限制抗体进入广泛中和 抗体(bnAb)表位。长期以来,2G 12一直是唯一一种仅与HIV-1相互作用的HIV-1 bnAb。 Env聚糖屏障。其独特的VH结构域交换架构,两个Fab臂交换以创建一个 Fab-二聚化IgG允许2G 12同时与4个聚糖相互作用,从而支持通常较弱的 蛋白质-聚糖通过亲合力结合。我们最近表征了结构多样的Fab二聚化, 靶向HIV-1 Env聚糖屏障的聚糖反应性(FDG)抗体。与2G 12不同,这些新发现的 FDG抗体不是结构域交换的;相反,Fab二聚化通过包括相互作用的机制发生。 Fab二硫键、疏水键和氢键相互作用。我们进一步表明,HIV-1 Env- 靶向FDG抗体识别SARS-CoV-2刺突的S2亚基中的聚糖簇。虽然我们的 结果揭示了抗体可以通过多种方式Fab二聚化来识别聚糖簇, 关于Fab二聚化和聚糖识别的机制仍然存在争议。了解这些将 提供了对B细胞对聚糖反应的发展的见解。 本研究的总体目标是了解抗体Fab二聚化的结构决定因素 导致高亲和力聚糖识别。2G 12和其他FDG bnAb特异性识别保守的 HIV-1 Env上的聚糖簇由独特的非自我呈现的自我糖组成,为以下方面提供了基础: 宿主和入侵病原体上的聚糖的免疫区分。科学的前提是 格兰特认为,定义Fab二聚抗体识别聚糖的结构机制将使 特异性靶向不同的糖基化病原体。该补助金的创新来自(一)扩大 FDG抗体库,(ii)FDG抗体普遍存在的证明,(iii) 结构域交换的VH构象对于HIV-1中和不是必需的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Priyamvada Acharya其他文献

Priyamvada Acharya的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Priyamvada Acharya', 18)}}的其他基金

Effect of natural and engineered variations on structure and biophysics of SARS-CoV-2 spike
自然和工程变异对 SARS-CoV-2 刺突结构和生物物理学的影响
  • 批准号:
    10558637
  • 财政年份:
    2022
  • 资助金额:
    $ 70.49万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10643907
  • 财政年份:
    2022
  • 资助金额:
    $ 70.49万
  • 项目类别:
Project 3 - Dynamics of latent HIV-1 reservoirs: High resolution antigenic mapping and strategies to block rebound
项目 3 - 潜在 HIV-1 储存库的动态:高分辨率抗原图谱和阻止反弹的策略
  • 批准号:
    10506669
  • 财政年份:
    2022
  • 资助金额:
    $ 70.49万
  • 项目类别:
Duke Center for HIV Structural Biology
杜克大学艾滋病毒结构生物学中心
  • 批准号:
    10643906
  • 财政年份:
    2022
  • 资助金额:
    $ 70.49万
  • 项目类别:
Core 1 - Structural Biology Core
核心 1 - 结构生物学核心
  • 批准号:
    10506664
  • 财政年份:
    2022
  • 资助金额:
    $ 70.49万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10506662
  • 财政年份:
    2022
  • 资助金额:
    $ 70.49万
  • 项目类别:
Dissecting the mechanisms of HIV resistance in vivo to broadly neutralizing antibodies
剖析 HIV 体内对广泛中和抗体的耐药机制
  • 批准号:
    10458981
  • 财政年份:
    2022
  • 资助金额:
    $ 70.49万
  • 项目类别:
Duke Center for HIV Structural Biology
杜克大学艾滋病毒结构生物学中心
  • 批准号:
    10506661
  • 财政年份:
    2022
  • 资助金额:
    $ 70.49万
  • 项目类别:
Core 1 - Structural Biology Core
核心 1 - 结构生物学核心
  • 批准号:
    10643911
  • 财政年份:
    2022
  • 资助金额:
    $ 70.49万
  • 项目类别:
Dissecting the mechanisms of HIV resistance in vivo to broadly neutralizing antibodies
剖析 HIV 体内对广泛中和抗体的耐药机制
  • 批准号:
    10680388
  • 财政年份:
    2022
  • 资助金额:
    $ 70.49万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 70.49万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.49万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 70.49万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.49万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 70.49万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 70.49万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.49万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 70.49万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 70.49万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.49万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了